Real-World data reveals how breast cancer patients use palbociclib in israel
NCT ID NCT04671615
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 23 times
Summary
This study looked at 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib as part of their treatment. Researchers tracked how long patients stayed on the drug, what doses they used, and what treatments they received next. The goal was to understand real-world use, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, 4672509, Israel
Conditions
Explore the condition pages connected to this study.